Zealand Pharma A/S (OTCMKTS:ZLDPF) Announces Quarterly Earnings Results, Beats Estimates By $1.45 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.57) by $1.45, Zacks reports. The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.33 million. Zealand Pharma A/S had a return on equity of 17.56% and a net margin of 58.86%.

Zealand Pharma A/S Price Performance

OTCMKTS ZLDPF remained flat at $35.50 during trading hours on Friday. The company’s stock had a trading volume of 515 shares, compared to its average volume of 526. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of 5.89 and a beta of 0.99. The company’s 50-day simple moving average is $38.62 and its 200 day simple moving average is $46.65. Zealand Pharma A/S has a 12 month low of $33.08 and a 12 month high of $83.12.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Zacks Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Zealand Pharma A/S currently has a consensus rating of “Hold”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.